[Asia Economy Reporter Lee Gwan-joo] Hyundai Bio announced on the 13th that the Phase 2 clinical trial of the oral antiviral drug for COVID-19, 'CP-COV03,' has been selected as a supported clinical trial by the National Clinical Trial Support Foundation.
The National Clinical Trial Support Foundation reportedly selected Hyundai Bio's CP-COV03 as a supported project on the 4th after a separate review by the Infectious Disease Clinical Trial Center consortium.
Accordingly, the Clinical Trial Support Foundation will assist with investigator (PI) connections and recruitment of clinical participants for Hyundai Bio's CP-COV03 Phase 2 trial. Patients diagnosed with COVID-19 will be able to apply for participation in the clinical trial through the 'COVID-19 Clinical Trial Portal' operated by the National Clinical Trial Support Foundation.
Meanwhile, since last month, the National Clinical Trial Support Foundation has been supporting patient recruitment and other activities through dedicated residential treatment centers at seven clinical institutions, including Seoul Medical Center, for Phase 3 oral treatments.
CP-COV03 is a 'host-targeted' antiviral drug that focuses its efficacy not on the virus but on the host cells. Hyundai Bio is conducting integrated Phase 2a/2b trials with 300 clinical participants to apply for emergency use authorization.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
